Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T14:45:29.308Z.
Calculation as of: 2026-10-06T14:45:29.308Z.
Quote observation: 2026-10-06T14:44:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 237c69f2886ce95022375c2c4ca3b4be9bdf1b13d47079a179ac8fcd7ebd926e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$16.58M
EV/EBIT Ratio
N/A
TTM Avg
188.96x
3Y Avg
135.60x
5Y Avg
135.60x
Market Cap
$14.44M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.98M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | $15.91M | N/A | N/A | N/A | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.42M | N/A | N/A | N/A | N/A |
| BioCardia, Inc. (BCDA)vs › | $15.92M | N/A | 33.55x | 33.49x | 33.49x |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.04M | N/A | N/A | N/A | N/A |
| Dyadic International, Inc. (DYAI)vs › | $16.58M | N/A | 188.96x | 135.60x | 135.60x |
| Bionano Genomics, Inc. (BNGO)vs › | $16.64M | N/A | N/A | N/A | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.44M | N/A | N/A | N/A | N/A |
| Lipocine Inc. (LPCN)vs › | $17.15M | N/A | 19.21x | 19.21x | 19.21x |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.98M | N/A | N/A | N/A | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.94M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
